Literature DB >> 10533808

Structure-activity relationship of hydroxamate-based inhibitors on membrane-bound Fas ligand and TNF-alpha processing.

M Yamamoto1, R Hirayama, K Naruse, K Yoshino, A Shimada, S Inoue, N Kayagaki, H Yagita, K Okumura, S Ikeda.   

Abstract

Both Fas ligand (FasL) and tumor necrosis factor-alpha (TNF-alpha) are type II integral membrane proteins. Recently, we have reported that FasL is processed to a soluble form by an unknown metalloproteinase at the cell surface and some hydroxamate matrix metalloproteinase (MMP) inhibitors inhibit the processing similar to the case observed with TNF-1alpha. We studied the inhibitory effects of various hydroxamate MMP inhibitors on FasL and TNF-alpha processing in order to characterize the processing enzymes using human FasL cDNA transfectants and LPS-stimulated THP-1 cells. It turned out that (1) the P1' group of hydroxamates was very important for the selective inhibitory activity toward TNF-alpha and FasL processing, (2) P1' 3-phenylpropyl group was favorable for the inhibition of FasL processing, and (3) P1' isobutyl and isopropyl groups were favorable for that of TNF-alpha processing. These differences in sensitivity to inhibitors imply that (1) membrane-bound FasL and TNF-alpha might be processed by distinct metalloproteinases, (2) the S1' site of FasL processing enzyme differs from that of MMP-1 and MMP-9, but appears to be similar to that of MMP-3, and (3) the S1' site of TNF-alpha processing enzyme is smaller than that of FasL processing enzyme. These results would be helpful in designing a more selective inhibitor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10533808

Source DB:  PubMed          Journal:  Drug Des Discov        ISSN: 1026-7921


  5 in total

1.  Vascular Dysfunction in Brain Hemorrhage: Translational Pathways to Developing New Treatments from Old Targets.

Authors:  Paul A Lapchak; Qiang Wu
Journal:  J Neurol Neurophysiol       Date:  2011

Review 2.  Hemorrhagic transformation following ischemic stroke: significance, causes, and relationship to therapy and treatment.

Authors:  Paul A Lapchak
Journal:  Curr Neurol Neurosci Rep       Date:  2002-01       Impact factor: 5.081

3.  Role of proteases in the pathophysiology of cardiac disease.

Authors:  Raja B Singh; Sucheta P Dandekar; Vijayan Elimban; Suresh K Gupta; Naranjan S Dhalla
Journal:  Mol Cell Biochem       Date:  2004-08       Impact factor: 3.396

4.  Hydroxamate-Based Selective Macrophage Elastase (MMP-12) Inhibitors and Radiotracers for Molecular Imaging.

Authors:  Kiran Gona; Jakub Toczek; Yunpeng Ye; Nowshin Sanzida; Arvene Golbazi; Parnaz Boodagh; Mani Salarian; Jae-Joon Jung; Saranya Rajendran; Gunjan Kukreja; Terence L Wu; Laurent Devel; Mehran M Sadeghi
Journal:  J Med Chem       Date:  2020-11-18       Impact factor: 7.446

Review 5.  Matrix metalloproteinases, new insights into the understanding of neurodegenerative disorders.

Authors:  Yoon-Seong Kim; Tong H Joh
Journal:  Biomol Ther (Seoul)       Date:  2012-03       Impact factor: 4.634

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.